Name

Alesta Therapeutics

Legal name

Alesta Therapeutics

Website

https://alestatherapeutics.com/

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Leiden

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech company. Plans to commercialize oral small molecule therapies for rare diseases (HPP, CMT) following successful clinical development and regulatory approval. Revenue will come from product sales through standard pharmaceutical distribution channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Alesta Therapeutics is a clinical-stage biotechnology company developing oral small molecule therapeutics for underserved rare genetic diseases. Its lead program, ALE1, is a first-in-class oral small molecule that inhibits a novel target to reduce inorganic pyrophosphate (PPi) levels for hypophosphatasia (HPP) and is in Phase 1/2a clinical development. The second program, ALE2, inhibits GCN2 to address specific tRNA-mutation forms of Charcot-Marie-Tooth (CMT) disease and is in preclinical development.

Product overview

Alesta Therapeutics is developing a portfolio of oral small molecule therapies for underserved rare diseases. The company's lead programs include ALE1 for hypophosphatasia (HPP) and ALE2 for Charcot-Marie-Tooth (CMT) disease. ALE1 is in Phase 1/2a clinical development while ALE2 is in preclinical development. Both programs utilize oral small molecules designed for patient-friendly administration with advantages in scalability, cost-effectiveness, and tissue penetration.

Differentiator

Problem solved

Functional benefit

Products and services

• ALE1 ALE1 is an orally active small molecule therapeutic candidate for hypophosphatasia (HPP), a rare genetic disorder caused by ALPL gene mutations leading to defective bone and tooth mineralization. ALE1 inhibits a novel target to reduce levels of inorganic pyrophosphate (PPi), a key metabolite central to HPP pathology, and is progressing through Phase 1/2a clinical development.
• ALE2 ALE2 is a small molecule therapeutic candidate targeting tRNA mutations that cause specific forms of Charcot-Marie-Tooth (CMT) disease. ALE2 inhibits GCN2, a key regulator of the Integrated Stress Response (ISR) that becomes activated by ribosomal stalling, to address chronic neurotoxicity in CMT patients. Currently in preclinical development.

Quantifiable outcome

• ALE1 demonstrated consistent PPi reduction across multiple animal models following oral dosing in preclinical studies
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• 1cBiocoreTechnology or IntegrationALE1 asset was in-licensed from 1cBio. The 1cBio team continues to support Alesta's development of the ALE1 program for HPP.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Pharnext: Pharnext is a late-stage biotech focused on Charcot-Marie-Tooth disease, with a pleotherapy approach (PXT-3003). It is the most directly comparable competitor for ALE2 in the specific CMT indication Alesta is targeting.
• Ionis Pharmaceuticals: Ionis is a clinical-stage RNA-targeted biotech with multiple programs in rare neurological diseases, including a development candidate for Charcot-Marie-Tooth disease (CMT). It is the most directly comparable peer for ALE2 and shares Alesta's antisense/small-molecule rare neurology strategy.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is a leading RNAi therapeutics company with multiple rare-disease products and a pipeline that includes neurological and metabolic rare disorders. Comparable in modality-adjacent rare-disease development and platform extensibility into additional indications.
• BridgeBio Pharma: BridgeBio is a clinical-stage rare-disease company with a portfolio model spanning genetic conditions including bone and neurological disorders. Its structure (multiple asset-focused subsidiaries pursuing rare-disease approvals) parallels Alesta's pipeline approach.
• Ultragenyx Pharmaceutical: Ultragenyx develops and commercializes therapeutics for rare and ultra-rare genetic diseases, including metabolic bone disorders. Highly relevant benchmark for Alesta's rare-disease, small-molecule development and commercialization model.
• Alexion / AstraZeneca Rare Disease: Alexion (now part of AstraZeneca) markets Strensiq (asfotase alfa), the only approved enzyme replacement therapy for HPP. It is the direct incumbent competitor for ALE1 in hypophosphatasia and shares the rare-disease commercialization playbook Alesta will need to build.
• BioMarin Pharmaceutical: BioMarin is an established rare-disease biotech commercializing enzyme replacement and small-molecule therapies for ultra-rare conditions. Comparable in commercial model (rare-disease pricing, specialty distribution) and in navigating regulators for genetic disorders.

Emerging players

• Solid Biosciences: Solid Biosciences is a clinical-stage genetic medicine company developing therapies for Duchenne muscular dystrophy and other rare diseases. Directly comparable in rare genetic disease focus and CEO lineage (Ilan Ganot co-founded and led Solid before joining Alesta).
• Minovia Therapeutics: Minovia Therapeutics is a clinical-stage biotech developing mitochondrial cell therapies for rare mitochondrial diseases. Directly connected to Alesta through CEO Ilan Ganot, who sits on Minovia's board, and shares Alesta's rare-disease clinical-development orientation.
• PepGen: PepGen is a clinical-stage biotech developing peptide-conjugated oligonucleotides for rare neuromuscular diseases, including CMT1A. Comparable as an emerging player in rare neuromuscular disease drug development targeting the same patient population as ALE2.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/alestatx

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alesta Therapeutics